Oxytocin Injection 10 IU Ml

It activates the phospholipase C pathway by binding to G protein coupled receptors on the membrane of uterine smooth muscle cells, increasing intracellular calcium ion concentration, thereby triggering regular uterine contractions, promoting cervical ripening (softening, dilation), and initiating delivery.

Clinical value: Studies have shown that the rational use of oxytocin induction can reduce the cesarean section rate by about 15% -20%, especially for pregnant women with a Bishop score of ≥ 6. For example, for patients with gestational hypertension, timely intervention can significantly reduce the risk of maternal cardiovascular and cerebrovascular complications; For patients with premature rupture of membranes, induced abortion can reduce the incidence of intrauterine infection.

It enhances the contractility of muscle fibers by regulating the phosphorylation level of contraction proteins in uterine smooth muscle cells, while coordinating the contraction rhythm of the upper and lower segments of the uterus, promoting fetal descent and cervical dilation.
Clinical value: In cases of labor stagnation caused by uterine atony, the use can shorten the labor process by an average of 4-6 hours and reduce the incidence of fetal distress by about 25%. For example, for the delivery of macrosomia (weight ≥ 4000g), it combined with positional management (such as lateral position) can significantly improve the success rate of vaginal delivery.

It takes effect quickly (peak concentration is reached 3-5 minutes after intravenous injection), has a short half-life (about 1-6 minutes), and requires continuous intravenous infusion (0.02-0.04 units/minute) to maintain hemostatic effect. For high-risk mothers (such as multiple pregnancies, polyhydramnios, and placenta previa), immediate intramuscular injection of 10 units of product can be administered as a preventive measure after the delivery of the fetus.
Clinical value: Clinical data shows that the use can reduce the incidence of postpartum hemorrhage by 40% -60%, making it a first-line hemostatic drug recommended by WHO. For example, in cesarean section, oxytocin injection 10 IU ml into the uterine muscle layer can reduce intraoperative bleeding by about 200-300ml and reduce the need for blood transfusion.

It can also regulate the remodeling of the extracellular matrix of uterine smooth muscle cells, accelerate muscle fiber retraction, reduce pelvic congestion and lower abdominal bloating.

Clinical value: For elderly mothers (≥ 35 years old), those with multiple pregnancies, or those who give birth to macrosomia, the use can shorten the time for uterine involution by 3-5 days and reduce the incidence of long-term complications such as uterine prolapse and chronic pelvic pain. For example, the use of oxytocin in the early postpartum period (within 24 hours) can significantly reduce the risk of late postpartum bleeding (bleeding within 24 hours to 6 weeks postpartum).

It Irritation Test (OCT): Induced regular contractions by intravenous infusion of product (initial dose 0.002 units/minute, increasing by 0.001 units/minute every 15 minutes to effective contractions), monitored fetal heart rate changes, evaluated placental reserve function, and diagnosed fetal distress risk.
Adjuvant treatment for central diabetes insipidus: By binding to the V2 receptor of renal tubular epithelial cells, it increases water reabsorption and reduces urine output (requiring multiple injections, 5-10 units each time). However, due to its short-term effect and potential to cause elevated blood pressure, it is only used as a temporary or auxiliary measure in clinical practice.
Breast milk secretion promotion: It can stimulate smooth muscle contraction around the mammary ducts, promote milk secretion, and is commonly used for postpartum milk stasis or breastfeeding difficulties (low-dose local use is required to avoid systemic side effects).